Related Experiment Video
Updated: Jun 24, 2025
05:54
Real-Time Dynamic Navigation System for the Precise Quad-Zygomatic Implant Placement in a Patient with a Severely Atrophic Maxilla
Published on: October 18, 2021
1.8K
Round and flat zygomatic implants: effectiveness after a 3‑year follow‑up non‑interventional study
Carlos Aparicio1,2, Waldemar D Polido3, Antoine Chehade4
1Zygomatic Unit, Hepler Bone Clinic, ZAGA Center Barcelona, Roman Macaya, 22-24, 08022, Barcelona, Spain. carlos.aparicio@zagacenters.com.
International Journal of Implant Dentistry
|June 10, 2024
Summary
Zygomatic implants (ZIs) using the Zygoma Anatomy-Guided Approach (ZAGA) show high survival rates and minimal late complications. This study confirms the effectiveness of ZAGA-based rehabilitation with Round and Flat zygomatic implant designs over a mean follow-up of 46.5 months.
Area of Science:
- Oral and Maxillofacial Surgery
- Dental Implantology
- Reconstructive Dentistry
Background:
- Zygomatic implants (ZIs) offer a solution for severe maxillary atrophy.
- The Zygoma Anatomy-Guided Approach (ZAGA) standardizes ZI placement.
- Long-term data on novel ZI designs and ZAGA is crucial.
Purpose of the Study:
- To investigate late complications of novel zygomatic implant designs.
- To assess outcomes of ZI placement using the ZAGA concept.
- To evaluate implant and prosthesis survival over a minimum 3-year follow-up.
Main Methods:
- Non-interventional study of patients receiving ZIs via ZAGA.
- Immediate loading of implants.
- Evaluation using ORIS success criteria (prosthetic offset, stability, sinus, soft tissue).
Main Results:
- 59 ZIs (Straumann ZAGA-Flat and ZAGA-Round) placed in 20 patients.
- 100% implant and prosthesis survival rate at a mean 46.5-month follow-up.
- Minimal changes in late complications compared to 1-year follow-up; 89.8% stable soft tissue.
Conclusions:
- ZAGA-based zygomatic implant rehabilitations are effective.
- Round and Flat ZI designs demonstrate favorable long-term outcomes.
- High survival rates and manageable late complications support ZAGA's clinical utility.
